DUBLIN, October 06, 2021– (BUSINESS WIRE) – “Global Gene Delivery Technologies Market 2021-2028” report has been added to ResearchAndMarkets.com offer.

The global gene delivery technology market size is expected to reach USD 7.9 billion by 2028. The market is expected to grow at a CAGR of 15.1% from 2021 to 2028.

Technological advancements in viral vectors, a growing pipeline of advanced therapies, and a growing number of regulatory approvals for advanced therapy products are some of the key driving forces in the market.

Several new tools are being introduced for genetic alterations that have enabled the scientific community to delineate the complexities of the disease at the genomic level, leading to the emergence of new approaches to gene delivery.

In addition, ongoing research to develop clinically relevant vectors, including viral and non-viral vectors, to fight chronic diseases such as cancer, Alzheimer’s disease and others through advanced therapies is stimulating market income.

An increase in investment and funding in space to support research, development and manufacture of various modes of gene transfer further accelerates revenue growth. Currently, approximately 70% of gene and cell therapy programs are based on viral vectors, resulting in organic revenue growth for bio-delivery technologies. Operational players are investing considerably to increase their capacity to manufacture viral vectors and meet growing demand.

Given the growing opportunities in physicochemical gene delivery approaches, the main players are deploying targeted efforts to strengthen their commercial presence.

For example, nanoparticles have proven their effectiveness as promising vehicles for clinical use due to their adjustable morphology and biological behaviors. Such ongoing developments in the space are expected to accelerate revenue growth in this market in the years to come.

Highlights of the Gene Delivery Technologies Market Report

The story continues

• The wide implementation of biological gene delivery technologies in clinical use due to their high efficiency and specificity resulted in the largest segment revenue share in 2020

• The development of Gene Therapy is the leading revenue generating application in the 2020 market due to the ever expanding therapy pipeline programs for life-threatening conditions coupled with the recent success of CAR-T therapies.

• The recent SARS-CoV-2 pandemic has also resulted in substantial global investments in the R&D of viral vector-based vaccines to combat the virus, leading to lucrative growth in this segment.

• The ex vivo method accounted for the bulk of the revenue due to its advantages such as high transduction efficiency and fewer immunogenic responses

• However, in vivo and ex vivo have shown clinical success in the treatment of chronic diseases, so both segments are expected to experience lucrative growth in the years to come.

• Given the high number of biotechnology companies and a favorable regulatory environment in the United States; North America dominates the global market in terms of turnover

• On the other hand, Asia-Pacific is expected to grow at the fastest pace during the forecast period

• The constantly changing CDMO and viral vector manufacturing landscapes through expansion of factories and construction of new sites in Asian countries are driving vector adoption in this region.

• Key players are engaged in collaboration with therapy developers to support their product development process

Market dynamics

Market Driver Analysis

• Advances in Gene and Cell Research and Therapeutic Delivery

• Increase in public and private funding

• Growing competition between market players

Analysis of market constraints

Analysis of market opportunities

Analysis of market challenges

Companies mentioned

• F. Hoffmann – La Roche SA

• Thermo Fisher Scientific, Inc.

• QIAGEN

• Horizon Discovery Group Co.

• OriGene Technologies, Inc.

• Oxford Biomedica

• SignaGen Laboratories

• Vectalys

• Takara Bio Inc.

• Bio – Rad Laboratories, Inc.

• Biosciences llc System

• Catalent Inc.

• Promega Company

• Agilent Technologies

• Sirion – Biotech GmbH

For more information on this report, visit https://www.researchandmarkets.com/r/3d8d3p

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211006005875/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Director
[email protected]

For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900